Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964639 | 0.92 | TBK1 (0.36) | KDM1ATBK1HRH3CYP2D6SGK1 | |
| SCHEMBL31079217 | 0.91 | MAPK1 (0.41) | MAPK1HRH3CYP2D6MAPKAPK2MAPK9 | |
| SCHEMBL29964448 | 0.89 | MAPKAPK2 (0.40) | MAPK1HRH3CYP2D6MAPKAPK2MAPK9 | |
| SCHEMBL31079223 | 0.89 | MAPK1 (0.41) | MAPK1HRH3CYP2D6MAPKAPK2MAPK9 | |
| SCHEMBL29964212 | 0.89 | TBK1 (0.43) | MAPK1KDM1ATBK1 | |
| SCHEMBL31079134 | 0.88 | MAPK1 (0.45) | MAPK1TBK1 | |
| SCHEMBL31079229 | 0.88 | MAPK1 (0.39) | MAPK1HRH3CYP2D6MAPKAPK2MAPK9 | |
| SCHEMBL29964177 | 0.87 | HRH3 (0.45) | MAPK1HRH3CYP2D6MAPKAPK2MAPK9 | |
| SCHEMBL29964560 | 0.87 | MAPK1 (0.39) | MAPK1KDM1ATBK1MAPKAPK2MAPK9 | |
| SCHEMBL29965165 | 0.87 | TBK1 (0.45) | MAPK1KDM1ATBK1SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | MAPK1 141/4885KDM1A 1020/4885TBK1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.